The contribution of optical coherence tomography in neuromyelitis optica spectrum disorders by Mateo, J. et al.
September 2017 | Volume 8 | Article 4931
Mini Review
published: 29 September 2017
doi: 10.3389/fneur.2017.00493
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Elena H. Martínez-Lapiscina, 
Hospital Clínic de Barcelona, Spain
Reviewed by: 
Hanna Gwendolyn Zimmermann, 
Charité Universitätsmedizin Berlin, 
Germany  
Christian Cordano, 
University of California, 
San Francisco, United States 
Andrés Cruz-Herranz, 
University of California, 
San Francisco, United States 
Lisanne Balk, 
VU University Medical Center, 
Netherlands
*Correspondence:
Andrzej Grzybowski  
ae.grzybowski@gmail.com
Specialty section: 
This article was submitted to 
Neuro-Ophthalmology, 






Mateo J, Esteban O, Martínez M, 
Grzybowski A and Ascaso FJ (2017) 
The Contribution of Optical 
Coherence Tomography 
in Neuromyelitis Optica 
Spectrum Disorders. 
Front. Neurol. 8:493. 
doi: 10.3389/fneur.2017.00493
The Contribution of Optical 
Coherence Tomography in 
neuromyelitis Optica Spectrum 
Disorders
Javier Mateo1, Olivia Esteban1, Mireya Martínez1, Andrzej Grzybowski2,3*  
and Francisco Javier Ascaso1,4
1 Department of Ophthalmology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 2 Department of 
Ophthalmology, Poznan City Hospital, Poznan, Poland, 3 Chair of Ophthalmology, University of Warmia and Mazury, Olsztyn, 
Poland, 4 Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain
Neuromyelitis optica spectrum disorders (NMOSD) comprises a group of central nervous 
system disorders of inflammatory autoimmune origin that mainly affect the optic nerves 
and the spinal cord and can cause severe visual and general disability. The clinical signs 
are similar to those of multiple sclerosis (MS), with the result that it is often difficult to 
differentiate between the two, thus leading to misdiagnosis. As the treatment and prog-
nosis of NMOSD and MS are different, it is important to make an accurate and early 
diagnosis of NMOSD. Optical coherence tomography (OCT) is a non-invasive technique 
that enables a quantitative study of the changes that the optic nerve and the macula 
undergo in several neurodegenerative diseases. Many studies have shown that some of 
these changes, such as retinal nerve fiber layer thinning or microcystic macular edema, 
can be related to alterations in the brain due to neurodegenerative disorders. The pur-
pose of this mini-review is to show how OCT can be useful for the diagnosis of NMOSD 
and follow-up of affected patients, as well as for the differential diagnosis with MS.
Keywords: neuromyelitis optica, optical coherence tomography, optic neuritis, multiple sclerosis, autoimmune 
diseases, Devic disease
inTRODUCTiOn
Neuromyelitis optica spectrum disorders (NMOSD), traditionally known as neuromyelitis optica or 
Devic disease, comprise a group of uncommon central nervous system (CNS) disorders of inflam-
matory autoimmune origin that mainly affect the optic nerves and/or the spinal cord (1–4).
Neuromyelitis optica spectrum disorders were first reported in the nineteenth century (5). 
Patients suffering from NMOSD can develop optic neuritis (ON) as well as transverse myelitis. ON, 
which is often the first manifestation of NMOSD, causes visual loss and painful eye movement, 
while myelitis can cause multiple alterations, such as sensory and movement disturbance, weakness, 
and loss of bowel and bladder control (1, 2, 5). Although these are the main clinical manifestations 
of the disease, other areas of the CNS can be affected, including the brain stem, diencephalon, area 
postrema on the dorsal surface of the medulla oblongata, and cerebrum (6–9). Alterations of the CNS 
due to NMOSD often generate severe visual and systemic disability (5, 10).
The clinical signs and symptoms of NMOSD are similar to those of multiple sclerosis (MS), thus 
making it difficult to perform a correct differential diagnosis (DD) between these two entities. As 
the treatment and prognosis of NMOSD and MS are different, it is important to make an accurate 
and early diagnosis of NMOSD (10). In general, ON is more severe and recurrent and more often 
Table 1 | Average peripapillary retinal nerve fiber thickness (in micrometers) 
after optic neuritis in patients with neuromyelitis optica spectrum disorders 




Range 31–99.4 44.4–129.5 80.8–128.1
Mean ± SD 63.6 ± 20.3 88.3 ± 16.5 102.4 ± 11.0
Schneider 
et al. (29)
Range 28–93.4 62.3–105.2 80.7–122.3
Mean ± SD 58.5 ± 21.2 85.3 ± 13.3 100.1 ± 10.8
Manogaran 
et al. (30)
Mean ± SD 70.8 ± 16.4 81.0 ± 12.8 100.1 ± 10.8




Park et al. (36) Mean ± SD 49.53 ± 3.81 70.09 ± 5.78 100.08 ± 9.34
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bilateral in NMOSD than in MS. In addition, visual impairment 
is more severe, and recovery is poorer in NMOSD (10–13). The 
finding of aquaporin-4 immunoglobulin G (AQP4-IgG) in blood 
considerably facilitates diagnosis, as it is present in most patients 
with NMOSD, but not in MS (5, 10, 14, 15). Magnetic resonance 
imaging (MRI) findings, such as optic chiasm involvement in ON 
or alteration of at least three contiguous segments of the spinal 
cord in transverse myelitis, are highly suggestive of NMOSD 
(16–18). A newer nomenclature of NMOSD is now being used 
to include patients with clinical syndromes and/or MRI find-
ings with or without AQP4-IgG. ON is not always present in 
NMOSD. In addition, antibodies against myelin oligodendrocyte 
glycoprotein (MOG-IgG) are found in one-third of patients with 
AQP4-IgG-seronegative NMOSD. MOG-IgG antibodies are use-
ful for the DD with MS. Furthermore, disease course is usually 
more favorable in patients with AQP4-IgG-seronegative and 
MOG-IgG-seropositive NMOSD (19, 20).
Optical coherence tomography (OCT) is a non-invasive 
imaging technique that was created in the 1990s and is currently 
used worldwide. It enables an in vivo quantitative and qualitative 
study of changes in the optic nerve and the macula (10, 21). It is 
fast, comfortable for the patient, and easy to perform and has, 
therefore, been used for several years to study many ophthalmic 
diseases, mainly glaucoma and macular disorders. In neuro-
ophthalmology, OCT is considered a “window” to the CNS, and 
is widely used to study neurodegenerative diseases such as MS, 
NMOSD, Alzheimer’s disease, and Parkinson’s disease (10, 22, 23).
In this mini-review, we show how OCT can lead to a faster and 
more accurate diagnosis and follow-up of NMOSD and also how 
it can help to differentiate NMOSD from other neurodegenera-
tive disorders, especially MS.
MeTHODS
We performed a literature search in PubMed in April 2017 using 
the terms “neuromyelitis optica” and “neuromyelitis optica spec-
trum disorders” combined with “optical coherence tomography” 
or “OCT.” We looked for original case-control studies, case series, 
or cohort studies, as well as reviews on the topic “neurodegenera-
tive disorders,” “multiple sclerosis,” “neuromyelitis optica,” “optic 
neuritis,” or “optic neuropathy.” We also reviewed many of the 
references of the articles found.
ReSUlTS
The most usual finding when OCT is used in patients with 
NMOSD is thinning of the peripapillary retinal nerve fiber 
layer (pRNFL). NMOSD studies, some cross-sectional studies, 
and cohort and prospective longitudinal studies show a marked 
decrease in pRNFL thickness after ON (11, 15, 23–27). As this 
finding is also observed in ON associated with other disorders, 
it does not facilitate the DD. However, many authors report that 
the decrease in pRNFL thickness and also in macular volume is 
more pronounced after ON in NMOSD than in MS (Table  1) 
(11, 15, 28–34). This could be explained by the fact that episodes 
of ON in NMOSD tend to be more severe and recovery poorer 
than in MS (Figure 1A) (11, 29, 30).
When differences in thinning of pRNFL are compared between 
NMOSD and MS, the damage in NMOSD affects every quadrant, 
mainly the superior and inferior quadrant, while in MS, it is more 
severe in the temporal quadrant (15, 24, 32, 35). Some authors 
state that this alteration of the different sectors of the pRNFL is 
caused by damage to the small-diameter axons—located mainly 
in the temporal quadrant—in MS and a more diffuse injury in 
NMOSD (15, 24).
Another frequent alteration highlighted by OCT in NMOSD 
is the reduced thickness of the ganglion cell layer (GCL) in the 
macula (10, 11, 15, 33, 36). This alteration has also been described 
in other neurodegenerative diseases, such as Alzheimer’s disease 
and MS (10, 37). However, it seems that the decrease in the thick-
ness of the GCL is more pronounced in NMOSD owing to intense 
inflammation and necrosis, with more prominent neuronal and 
axonal damage in NMOSD than in MS (11, 36). The more severe 
thinning of the superior quadrant of the GCL, which is similar 
to that observed in anterior ischemic optic neuropathy (AION), 
suggests vascular and ischemic damage to the optic nerve in 
NMOSD (36, 38). Recent investigations show foveal thinning 
in NMOSD patients with or without ON, indicating damage to 
the retina, perhaps because Müller cells and retinal astrocytes 
expressing AQP4 are targeted in NMOSD, even when there is no 
history of ON (39–41).
In some cases of NMOSD, microcystic macular edema can 
affect the inner nuclear layer of the retina after ON, a feature that 
has also been described in other conditions of the optic nerve, 
such as Leber hereditary optic neuropathy, AION, MS, compres-
sive or traumatic optic neuropathy, hydrocephalus, and even 
glaucoma. The origin of this edema remains unclear, although 
the main hypotheses are trans-synaptic degeneration and vitre-
ous traction (15, 21, 24, 42, 43).
When ON is not present in NMOSD, there also seem to be 
differences between MS and NMOSD. While in MS there is 
significant subclinical thinning of the pRNFL, especially in the 
temporal quadrant, this damage does not occur or is very subtle 
in NMOSD without ON (Figure 1B) (15, 26–29). Nevertheless, 
there does seem to be a subclinical decrease in the thickness 
of the GCL and macular thickness in NMOSD without ON 
(11, 15, 24, 30, 44, 45). This might be caused by damage of the 
Müller cells in the retina (see above). These cells are rich in AQP4 
channels, which are attacked in NMOSD (11, 45).
FigURe 1 | (a) Severe atrophy of peripapillary retinal nerve fiber layer (pRNFL) after optic neuritis (ON) in a neuromyelitis optica spectrum disorders patient.  
(b) Atrophy of pRNFL temporal quadrant in a multiple sclerosis patient without history of ON.
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A relationship can be observed between OCT changes and 
clinical features in NMOSD. For example, the decrease in pRNFL 
thickness and macular volume is apparently associated with 
the degree of visual disability in NMOSD, and the same can be 
observed with the decrease in the thickness of the GCL. Similar 
effects can be observed in MS (10, 15, 24, 33, 46). Although while 
in MS there is a clear correlation between the reduction in pRNFL 
and GCL thickness and general disability, this correlation has not 
been reported as frequently in NMOSD (15, 26, 47–50).
DiSCUSSiOn
Although OCT alone cannot confirm the DD between NMOSD 
and MS, it is highly accurate and plays a useful role in the follow-
up of NMOSD.
The diagnostic criteria for NMOSD include clinical features 
(mainly ON and acute myelitis), the presence of AQP4-IgG in 
most patients, and characteristic MRI findings (3).
Owing to the similarities between NMOSD and MS, it is 
sometimes difficult to discriminate between both entities. 
Combination of OCT and the aforementioned diagnostic criteria 
can enable a more precise DD.
During the acute and early phase of ON, when the optic nerve 
head is swollen and the pRNFL does not provide reliable data, 
OCT is particularly useful for assessment of the GCL, which is 
frequently more severely affected in NMOSD than in MS (33).
Other OCT changes that can facilitate the DD are thinning of 
the pRNFL and GCL and reduction in macular volume, which 
are usually more severe in NMOSD than in MS after ON (11, 15). 
These changes, which predominantly affect the superior and 
inferior quadrants, are suggestive of NMOSD, while damage in 
the temporal quadrant points to MS (15, 24).
In cases of suspicion of NMOSD without ON, the thinning 
of the temporal quadrant of the pRNFL is characteristic of MS 
rather than NMOSD, since in the latter, pRNFL is only slightly 
affected or unaffected (15, 24).
Because of the relationship between damage to visual func-
tion and the decrease in pRNFL, macular volume, and the GCL, 
OCT could prove to be a valuable instrument for the follow-up 
of NMOSD (10, 15, 24).
Further studies are necessary to provide more evidence and 
show us the extent of the usefulness of OCT for the diagnosis, 
study, and follow-up of NMOSD.
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